Table 3. Effect of metformin given from various age on life span in female SHR mice.
| Parameters | Control-3 | MF-3 | Control-9 | MF-9 | Control-15 | MF-15 |
|---|---|---|---|---|---|---|
| No. of mice at start of the treatment | 119 | 51 | 97 | 45 | 69 | 33 |
| Mean life span, days | 511 ± 20.3 | 583 ± 26.7 (+14.1%) | 583 ± 17.9 | 619 ± 19.5 (+6.2%) | 668 ± 15.7 | 647 ± 21.4 |
| Median, days | 525 | 617 | 591 | 630 | 636 | 636 |
| Mean life span of last 10%, days | 881 ± 12.8 | 897 ± 27.8 | 892 ± 12.4 | 820 ± 14.1 | 913 ± 8.8 | 892 ± 47.0 |
| Maximum life span, days | 941 | 972 | 941 | 855 | 941 | 966 |
| α × 103, days−1 | 3.7 (3.2; 3.9) | 5.2* (4.9; 5.3) | 4.1 (3.9; 4.2) | 7.8* (7.7; 8.2) | 4.7 (4.6; 4.8) | 4.3* (4.2; 4.5) |
| MRDT, days | 187 (178; 217) | 133* (131; 141) | 169 (165; 178) | 89* (85; 90) | 147 (144; 151) | 161* (154; 165) |
| No. of tumor-free mice | 62 | 25 | 45 | 15 | 29 | 16 |
| Mean life span of tumor-free mice, days | 478 ± 32.7 | 577 ± 44.3 (+20.7%) | 609 ± 29.7 | 652 ± 31.5 (+7.1%) | 719 ± 23.9 | 627 ± 25.5* (−12.8%) |
MRDT, mortality rate doubling time; in brackets - 95% confidential interval.
*
The difference with the relevant controls is significant, p < 0.05.